Comparative effectiveness study of chemotherapy in follicular lymphoma patients in the rituximab era: a Japanese claims database study.

Abstract

Aim: To evaluate comparative effectiveness of rituximub (R)-based versus non-R-based therapies for follicular lymphoma patients in Japan, where limited studies have been reported. Materials & methods: Patients who received R-based index regimens were propensity score matched to those who did not receive R, based on patient baseline attributes and clinical characteristics using Japanese retrospective claims database to assess clinical and economic outcomes. Results & conclusion: A total of 1947 patients remained in the overall follicular lymphoma cohorts: 1294 receiving an R-based and 653 a non-R-based regimen. Patients on R-based therapy underwent fewer hospitalizations and had a shorter length of stay, but had higher costs during the first year of intensive R-based therapy. Improved clinical outcomes were associated with patients who were younger, female and chose R-based regimens in first index line.

• Authors: Saaya Tsutsué, Kensei Tobinai, Jingbo Yi, Bruce Crawford
• Journal: Future oncology (London, England) (Future Oncol) Vol. 17 Issue 4 Pg. 455-469 (Feb 2021) ISSN: 1744-8301 [Electronic] England
• PMID: 33021099 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Rituximab

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Databases, Factual
• Female
• Health Care Costs
• Health Resources
• Humans
• Lymphoma, Follicular (drug therapy, mortality)
• Male
• Middle Aged
• Propensity Score
• Rituximab (administration & dosage, therapeutic use)
• Young Adult